Global Virus Network Statement on H5N1 Vaccine Developments
The Global Virus Network (GVN), representing eminent human and animal virologists from more than 90 Centers of Excellence and Affiliates in over 40 countries dedicated to advancing research, collaboration, and pandemic preparedness, unequivocally supports and is very encouraged by recent developments in vaccines targeting H5N1 avian influenza, including the initiation of a Phase 3 clinical trial by Moderna for its mRNA-based H5N1 vaccine candidate (mRNA-1018), with the majority of clinical sites based in the United Kingdom and additional sites in the United States. This effort, supported by the UK’s National Institute for Health and Care Research...
To Read Full Story Login Below.
Submit comment or question
Note: All comments are displayed with user's screen name. If screen name is not present, user's full name will be used. Please go to My Account to update your screen name.
Comment Policy: Urner Barry has made the comment feature available to encourage further discussion of our news stories. Defamatory or offensive comments, or comments deemed not relevant to the story will be removed, and if necessary, Urner Barry may restrict the right of individual subscribers to offer comments. In all cases, comments represent opinions of the poster only, and do not represent fact, news, opinions or estimates put forward by Urner Barry.
Email Address is required. Password is required.